However,because stable STING agonists would elicit systemic inflammation ifreleased prematurely or leaked from the tumor site, caution shouldbe used in applying STING ADCs with a slow systemic clearance of theirwarheads.66 Effort toward addressing thesafe use of STING agonists in vivo through ADC optimization is underway. The gene discussed is STING1; the disease is neoplasm.